Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 20:20:100561.
doi: 10.1016/j.jvacx.2024.100561. eCollection 2024 Oct.

Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months

Nasamon Wanlapakorn  1 , Nasiri Sarawanangkoor  1 , Donchida Srimuan  1 , Thaksaporn Thatsanathorn  1 , Sirapa Klinfueng  1 , Yong Poovorawan  1   2
Affiliations

Persistence of hepatitis B surface antibody until 7 years of age following administration of hexavalent and pentavalent vaccines in children at 2, 4, 6, and 18 months

Nasamon Wanlapakorn et al. Vaccine X. .

Abstract

Thailand incorporated the hepatitis B (HepB) vaccine into the infant combination vaccine known as pentavalent wP-containing vaccines (DTwP-HB-Hib) and hexavalent aP-containing vaccines (DTaP-IPV-HB-Hib). We followed healthy children from the clinical trial (ClinicalTrials.gov NCT02408926) in which children were randomly assigned to receive either pentavalent or hexavalent vaccines for their primary series (administered at 2, 4, and 6 months) and first booster vaccination (at 18 months), following the monovalent HepB vaccine at birth. Blood samples were collected to evaluate the persistence of hepatitis B surface antibody (anti-HBs) at 3, 4, 5, 6 and 7 years of age. The results showed that at 7 years of age, a higher percentage of children in the hexavalent group maintained anti-HBs levels ≥ 10 mIU/mL compared to those in the pentavalent group (86.9 % vs. 59.7 %). This study showed good persistence of anti-HBs among hexavalent-vaccinated children 5.5 years after the last dose of the HepB vaccine.

Keywords: Antibody; Childhood; Hepatitis; Hexavalent; Pentavalent; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Geometric mean concentrations (GMCs) of anti-HBs from birth to 7 years among the hexavalent, pentavalent, and EPI pentavalent groups. Data from birth to month 24 were previously published . Syringes indicate the time point of primary and booster vaccinations. The number of doses received was indicated in the box next to the syringes.
See this image and copyright information in PMC

References

    1. Posuwan N., Wanlapakorn N., Sa-Nguanmoo P., Wasitthankasem R., Vichaiwattana P., Klinfueng S., et al. The success of a universal hepatitis B immunization program as part of Thailand's EPI after 22 years' implementation. PLoS One. 2016;11:e0150499. - PMC - PubMed
    1. Chunsuttiwat S., Biggs B.A., Maynard J.E., Thammapormpilas P., O-Prasertsawat M. Comparative evaluation of a combined DTP-HB vaccine in the EPI in Chiangrai Province, Thailand. Vaccine. 2002;21:188–193. doi: 10.1016/s0264-410x(02)00461-9. - DOI - PubMed
    1. Wanlapakorn N., Pruetarat N., Sarawanangkoor N., Phanphanit K., Srimuan D., Thatsanathorn T., et al. Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age. Vaccine. 2023;41:3855–3861. doi: 10.1016/j.vaccine.2023.05.014. - DOI - PubMed
    1. Posuwan N., Wanlapakorn N., Vongpunsawad S., Sintusek P., Leuridan E., Van Damme P., et al. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine. 2020;38:1643–1651. doi: 10.1016/j.vaccine.2019.12.065. - DOI - PubMed
    1. Wanlapakorn N., Sarawanangkoor N., Srimuan D., Thatsanathorn T., Thongmee T., Poovorawan Y. Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines. Hum Vaccin Immunother. 2024;20:2352909. doi: 10.1080/21645515.2024.2352909. - DOI - PMC - PubMed

Associated data

LinkOut - more resources